Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation



Status:Terminated
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:June 2013
End Date:July 2014

Use our guide to learn which trials are right for you!

A Prospective, Randomized, Multicenter, Two-Parallel Arm Study Evaluating the Overall Efficacy and Safety of Desensitization Therapy on Selected Patients Awaiting Heart Transplantation

The primary objective is to evaluate the efficacy of desensitization therapy, which includes
VELCADE® (bortezomib) and plasmapheresis, on select sensitized patients awaiting heart
transplantation.

Bortezomib works by decreasing plasma cells in the blood. Plasma cells produce antibodies.
Plasmapheresis is a procedure that removes antibodies from the blood. Plasma cells and
antibodies produced by plasma cells can be involved in organ rejection after
transplantation.

This trial will evaluate if decreasing plasma cells and antibodies with bortezomib and
plasmapheresis can reduce complications while participants are waiting for their heart
transplant. The evaluation of efficacy is defined by a lower complication rate while on the
heart transplant waitlist.

Inclusion Criteria:

- Subject must be able to understand and provide informed consent;

- Candidate (as recipient) for a primary heart transplant (single organ transplant);

- Calculated panel reactive antibody (cPRA) of greater than 30% with a threshold using
mean fluorescent intensity (MFI) of 3,000 or standard fluorescence intensity (SFI) of
60,000;

- Status 1 (1A or 1B) enrollment and randomization to occur within 2 weeks after status
1 listing;

- Female subject is either postmenopausal for at least 1 year before the screening
visit, is surgically sterilized or if they are of childbearing potential, agree to
practice 2 effective methods of contraception from the time of signing the informed
consent form through 30 days after the last dose of bortezomib, or agree to
completely abstain from heterosexual intercourse;

- Male subjects, even if surgically sterilized (i.e., status postvasectomy) must agree
to 1 of the following: practice effective barrier contraception during the entire
study treatment period and through a minimum of 30 days after the last dose of study
drug, or completely abstain from heterosexual intercourse;

- Negative test for HIV (human immunodeficiency virus), HBsAg (hepatitis B surface
antigen), HBcAb (hepatitis B core antibody), and HCV (hepatitis C virus) antibodies
within 6 months prior to study entry.

Exclusion Criteria:

- Recipient of multiple solid organ or tissue transplants;

- Prior history of organ transplantation;

- Women of childbearing potential with a positive serum β-human chorionic gonadotropin
(β-hCG) pregnancy test.Pregnancy testing is not required for postmenopausal or
surgically sterilized women;

- Currently breast-feeding a child or plans to become pregnant during the timeframe of
the study follow-up period;

- Subject has a hypersensitivity to VELCADE® (bortezomib), boron, or mannitol;

- Active systemic infection at time of enrollment;

- Any history of serologic positivity to HIV, HBsAg, HBcAb and HCV Ab;

- History of malignancy except when noted by an oncology specialist that tumor
recurrence is low based on tumor type, response to therapy and negative metastatic
work-up;

- Radiation therapy within 3 weeks before randomization. Enrollment of subjects who
require concurrent radiotherapy (which must be localized in its field size) should be
deferred until the radiotherapy is completed and 3 weeks have elapsed since the last
date of therapy;

- Subjects with a platelet count of less than 75,000 within 7 days prior to enrollment;

- Subjects with an absolute neutrophil count (ANC) of less than 1,500 within 7 days
prior to enrollment;

- Subjects with >1.5 x ULN (upper limit of normal) total bilirubin;

- Subjects with any grade or history of neuropathy;

- Any condition that, in the opinion of the investigator, would interfere with the
subject's ability to comply with study requirements;

- Participation in another interventional clinical trial or requiring treatment using
un-marketed investigational drug(s) within 14 days of start of this trial and
throughout the duration of this trial.
We found this trial at
14
sites
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Beverly Hills, California 90211
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
303 E Chicago Ave
Chicago, Illinois 60611
(312) 503-8194
Northwestern University Feinberg School of Medicine Northwestern University Feinberg School of Medicine, founded in 1859,...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Minneapolis, Minnesota 55407
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
5121 S Cottonwood St
Murray, Utah 84157
(801) 507-7000
Intermountain Medical Center Intermountain Medical Center is one of the most technologically advanced and patient-friendly...
?
mi
from
Murray, UT
Click here to add this to my saved trials
20 York St, N20 York St,
New Haven, Connecticut 06520
(203) 688-4242
Yale-New Haven Hospital Relying on the skill and expertise of more than 4,500 university and...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New York, New York 10029
?
mi
from
New York, NY
Click here to add this to my saved trials
2900 W Queen Ln
Philadelphia, Pennsylvania 19129
(215) 991-8100
Drexel University College of Medicine Drexel University College of Medicine represents the consolidation of two...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials